Liraglutide in polycystic ovary syndrome: a randomized trial, investigating effects on thrombogenic potential
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
Polycystic ovary syndrome (PCOS) is associated with increased risk of venous thromboembolism (VTE) and cardiovascular disease (CVD) in later life. We aimed to study the effect of liraglutide intervention on markers of VTE and CVD risk, in PCOS. In a double-blind, placebo-controlled, randomized trial, 72 overweight and/or insulin-resistant women with PCOS were randomized, in a 2:1 ratio, to liraglutide or placebo 1.8 mg/day. Endpoints included between-group difference in change (baseline to follow-up) in plasminogen activator inhibitor-1 levels and in thrombin generation test parameters: endogenous thrombin potential, peak thrombin concentration, lag time and time to peak. Mean weight loss was 5.2 kg (95% CI 3.0–7.5 kg, P < 0.001) in the liraglutide group compared with placebo. We detected no effect on endogenous thrombin potential in either group. In the liraglutide group, peak thrombin concentration decreased by 16.71 nmol/L (95% CI 2.32–31.11, P < 0.05) and lag time and time to peak increased by 0.13 min (95% CI 0.01–0.25, P < 0.05) and 0.38 min (95% CI 0.09–0.68, P < 0.05), respectively, but there were no between-group differences. There was a trend toward 12% (95% CI 0–23, P = 0.05) decreased plasminogen activator inhibitor-1 in the liraglutide group, and there was a trend toward 16% (95% CI −4 to 32, P = 0.10) reduction, compared with placebo. In overweight women with PCOS, liraglutide intervention caused an approximate 5% weight loss. In addition, liraglutide affected thrombin generation, although not significantly differently from placebo. A concomitant trend toward improved fibrinolysis indicates a possible reduction of the baseline thrombogenic potential. The findings point toward beneficial effects of liraglutide on markers of VTE and CVD risk, which should be further pursued in larger studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Some studies compared the liraglutide 1.8 mg/day vs. placebo for 26 weeks and demonstrated a greater efficacy in terms of reduction of body weight and waist circumference (WC) in the liraglutide group [54–56].”
From Liraglutide and polycystic ovary syndrome: is it only a matter of body weight? (2023) · cites this paper as [56]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Yaşlı Kadınlarda Üreme Sağlığı
Kokanalı, D., & Engin Üstün, Y. (n.d.) · DergiPark (Istanbul University) · Cited by 170,090
Correspondence - Tranexamic acid for traumatic brain injury
(2005) · London School of Economics and Political Science Theses Online (London School of Economics and Political Science) · doi:10.1016/s0140-6736 · Cited by 11,894
(2004) · Fertility and Sterility · doi:10.1016/j.fertnstert.2003.10.004 · Cited by 9,050
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
Bozdag, G., Mumusoglu, S., Zengin, D., Karabulut, E., & Yildiz, B. O. (2016) · Human Reproduction · doi:10.1093/humrep/dew218 · Cited by 1,526
Garber, A., Henry, R., Ratner, R., Garcia-Hernandez, P. A., Rodriguez-Pattzi, H., Olvera-Alvarez, I., Hale, P. M., Zdravkovic, M., & Bode, B. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61246-5 · Cited by 1,057
Vilsboll, T., Christensen, M., Junker, A. E., Knop, F. K., & Gluud, L. L. (2012) · BMJ · doi:10.1136/bmj.d7771 · Cited by 970
Thrombin generation and fibrin clot structure
Wolberg, A. S. (2007) · Blood Reviews · doi:10.1016/j.blre.2006.11.001 · Cited by 747
Cited by
Characteristics of obesity in polycystic ovary syndrome: Etiology, treatment, and genetics
Glueck, C. J., & Goldenberg, N. (2019) · Metabolism · doi:10.1016/j.metabol.2018.11.002 · Cited by 442
Salamun, V., Jensterle, M., Janez, A., & Vrtacnik Bokal, E. (2018) · European Journal of Endocrinology · doi:10.1530/eje-18-0175 · Cited by 204
Effect of liraglutide on ectopic fat in polycystic ovary syndrome: Arandomized clinical trial
Frøssing, S., Nylander, M., Chabanova, E., Frystyk, J., Holst, J. J., Kistorp, C., Skouby, S. O., & Faber, J. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13053 · Cited by 178
“The LIPT-study was a double-blind, placebo-controlled RCT.8 In short, inclusion criteria were PCOS (Rotterdam criteria), BMI > 25 kg/m2 and/or presence of IR.”
MethodSelf-citationPolycystic ovarian syndrome-current pharmacotherapy and clinical implications
Rashid, R., Mir, S. A., Kareem, O., Ali, T., Ara, R., Malik, A., Amin, F., & Bader, G. N. (2022) · Taiwanese Journal of Obstetrics and Gynecology · doi:10.1016/j.tjog.2021.11.009 · Cited by 156
Polycystic Ovary Syndrome: Pathophysiology and Therapeutic Opportunities
Dong, J., & Rees, D. A. (2023) · BMJ Medicine · doi:10.1136/bmjmed-2023-000548 · Cited by 123
“136 137 A meta-analysis of eight randomised controlled trials concluded that GLP-1 agonists were more effective than metformin in improving homeostasis model assessment-insulin resistance (standard mean difference −0.40, 95% confidence interval −0.74 to −0.06), abdominal circumference (−0.45, −0.89…”
Influential
Metadata
- Authors
- Nylander, M., Frøssing, S., Kistorp, C., Faber, J., & Skouby, S. O.
- Affiliations
- University of Copenhagen (DK)
- Corresponding author
- Nylander, Malin
- Venue
- Endocrine Connections
- Publisher
- Bioscientifica
- Published
- 2017-02
- Volume
- 6
- Issue
- 2
- Pages
- 89-99
- ISSN
- 2049-3614 (ISSN-L)
- PMC
- PMC5424770
- OpenAlex
- W2580304737
- Cited by
- 44
- References
- 48
- Citations by year
- 2026: 10 · 2025: 7 · 2024: 4 · 2023: 5 · 2022: 2 · 2021: 3 · 2020: 4 · 2019: 1 · 2018: 5 · 2017: 3
- FWCI
- 4.13
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Endocrine Connections (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, cc-by-nc)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Gentofte Hospital
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Keywords
- polycystic ovary syndrome, liraglutide, venous thromboembolism, cardiovascular risk, thrombogenic potential, thrombin generation, plasminogen activator inhibitor-1, fibrinolysis, weight loss, insulin resistance, overweight women, GLP-1 receptor agonists, endogenous thrombin potential, time delay
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Liraglutide in polycystic ovary syndrome: a randomized trial, investigating effects on thrombogenic potential. https://app.cochat.ai/papers/10.1530/ec-16-0113
- The paper
- Nylander, M., Frøssing, S., Kistorp, C., Faber, J., & Skouby, S. O. (2017). Liraglutide in polycystic ovary syndrome: a randomized trial, investigating effects on thrombogenic potential. Endocrine Connections. https://doi.org/10.1530/ec-16-0113
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.